Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1089/jir.2020.0105 http://scihub22266oqcxt.onion/10.1089/jir.2020.0105 32881593!ä!32881593 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Interferon+Cytokine+Res 2020 ; 40 (10): 469-471 Nephropedia Template TP {{tp|p=32881593|t=2020. Impact of Hydroxychloroquine/Chloroquine in COVID-19 Therapy: Two Sides of the Coin |pdf=|usr=}}{{32881593}} gab.com Text Impact of Hydroxychloroquine/Chloroquine in COVID-19 Therapy: Two Sides of the Coin JO: J Interferon Cytokine Res http://www.kidney.de/pget.php?&tw=1&pmid=32881593 #FOAvip Coronavirus disease 2019 (COVID-19), which is caused by a novel severe acute respiratory syndrome coronavirus (SARS-CoV-2), has recently emerged as a global health threat. To address this health emergency, various therapeutic approaches are currently under investigation. There is limited evidence on the effectiveness of hydroxychloroquine (HCQ) and chloroquine (CQ) as COVID-19 therapies, and thus World Health Organization (WHO) mentioned that "Current data shows that this drug does not reduce deaths among hospitalized COVID-19 patients, nor help people with mild or moderate disease." CQ and HCQ are typically used for the treatment of malaria but have been recognized for certain beneficial effects in COVID-19 patients based on some clinical outcomes from the clinical treatment of COVID-19. A standard dose of HCQ has been proven effective and less toxic than CQ in COVID-19 patients; however, a comprehensive understanding of a patient's clinical condition is necessary. Based on several hospital findings, the Food and Drug Administration (FDA) has officially cancelled the emergency use authorization for HCQ and CQ for treating hospitalized COVID-19 patients on June 15, 2020. In this review, we highlight both pros and cons of the clinical use of CQ and HCQ in COVID-19 patients. Twit Text FOAVip Impact of Hydroxychloroquine/Chloroquine in COVID-19 Therapy: Two Sides of the Coin ????J Interferon Cytokine Res http://www.kidney.de/pget.php?&tw=1&pmid=32881593 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32881593 #FOAvip English Wikipedia <ref>{{Cite pmid|32881593}}</ref> Impact of Hydroxychloroquine/Chloroquine in COVID-19 Therapy: Two Sides of the Coin #MMPMID32881593 Fatima U; Rizvi SSA; Fatima S; Hassan MI J Interferon Cytokine Res 2020[Oct]; 40 (10): 469-471 PMID32881593show ga Coronavirus disease 2019 (COVID-19), which is caused by a novel severe acute respiratory syndrome coronavirus (SARS-CoV-2), has recently emerged as a global health threat. To address this health emergency, various therapeutic approaches are currently under investigation. There is limited evidence on the effectiveness of hydroxychloroquine (HCQ) and chloroquine (CQ) as COVID-19 therapies, and thus World Health Organization (WHO) mentioned that "Current data shows that this drug does not reduce deaths among hospitalized COVID-19 patients, nor help people with mild or moderate disease." CQ and HCQ are typically used for the treatment of malaria but have been recognized for certain beneficial effects in COVID-19 patients based on some clinical outcomes from the clinical treatment of COVID-19. A standard dose of HCQ has been proven effective and less toxic than CQ in COVID-19 patients; however, a comprehensive understanding of a patient's clinical condition is necessary. Based on several hospital findings, the Food and Drug Administration (FDA) has officially cancelled the emergency use authorization for HCQ and CQ for treating hospitalized COVID-19 patients on June 15, 2020. In this review, we highlight both pros and cons of the clinical use of CQ and HCQ in COVID-19 patients. |Anti-Infective Agents/*administration & dosage/adverse effects[MESH] |Azithromycin/therapeutic use[MESH] |Betacoronavirus/*drug effects/growth & development/pathogenicity[MESH] |COVID-19[MESH] |Chloroquine/*administration & dosage/adverse effects[MESH] |Clinical Trials as Topic[MESH] |Coronavirus Infections/*drug therapy/pathology/virology[MESH] |Drug Synergism[MESH] |Humans[MESH] |Hydroxychloroquine/*administration & dosage/adverse effects[MESH] |Immunologic Factors/*administration & dosage/adverse effects[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/pathology/virology[MESH] |SARS-CoV-2[MESH]Impact of Hydroxychloroquine/Chloroquine in COVID-19 Therapy: Two Side(epmc).pdf DeepDyve Pubget Overpricing